

Norbert Arnold

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9347411/norbert-arnold-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

8,240
citations

48
h-index

85
g-index

181
ext. papers

9,741
ext. citations

6.4
avg, IF

4.6
L-index

#	Paper	IF	Citations
176	ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
175	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 893-899	9.7	4
174	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
173	Aktualisierte Kriterien des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zur Klassifizierung von Keimbahn-Sequenzvarianten in Risikogenen für familiären Brust- und Eierstockkrebs. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 136-162	0	0
172	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
171	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
170	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
169	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020 , 10, 9688	4.9	2
168	Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 410-429	2	6
167	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
166	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. <i>Journal of Leukocyte Biology</i> , 2020 , 107, 1081-1095	6.5	17
165	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
164	Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020 , 146, 999-1009	7.5	18
163	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
162	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019 , 121, 180-192	8.7	13
161	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , 2019 , 10, 523-530	2.5	4
160	Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. <i>Breast Cancer Research</i> , 2019 , 21, 55	8.3	25

159	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. <i>BMC Cancer</i> , 2019 , 19, 787	4.8	3
158	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
157	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. <i>Oncotarget</i> , 2019 , 10, 6494-6508	3.3	11
156	The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. <i>International Journal of Cancer</i> , 2019 , 144, 1761-1763	7.5	1
155	Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancer Medicine</i> , 2018 , 7, 1349-1358	4.8	71
154	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
153	Changes in classification of genetic variants in BRCA1 and BRCA2. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 297, 279-280	2.5	6
152	Reply to letter by Dr. G. Corso. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 297, 1069	2.5	
151	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. <i>Journal of Medical Genetics</i> , 2018 , 55, 15-20	5.8	36
150	CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 297, 147-152	2.5	8
149	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. <i>Breast Cancer Research</i> , 2018 , 20, 7	8.3	47
148	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018 , 18, 265	4.8	43
147	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 16043-16058	3.3	11
146	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. <i>Oncotarget</i> , 2018 , 9, 32362-32372	3.3	1
145	Quantifying cell free DNA in urine: comparison between commercial kits, impact of gender and inter-individual variation. <i>BioTechniques</i> , 2018 , 64, 225-230	2.5	20
144	Metastatic triple-negative breast cancer patient with tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. <i>Journal of Physical Education and Sports Management</i> , 2017 , 3,	2.8	9
143	Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. <i>Archives of Gynecology and Obstetrics</i> , 2017 , 295, 1227-1238	2.5	11
142	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190

141	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
140	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
139	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
138	NGS-based multi-gene panel analysis in BRCA1/2-negative breast and ovarian cancer families.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1526-1526	2.2	
137	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
136	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016 , 18, 112	8.3	25
135	Personalisierte Medizin bei soliden Tumoren. <i>Medizinische Genetik</i> , 2016 , 28, 443-451	0.5	
134	Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. <i>Archives of Gynecology and Obstetrics</i> , 2016 , 294, 813-23	2.5	3
133	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016 , 25, 2256-2268	5.6	55
132	Alteration of STR profiles in ovarian carcinoma cells during primary culture. <i>Archives of Gynecology and Obstetrics</i> , 2016 , 294, 369-76	2.5	6
131	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
130	BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1090-1090	2.2	1
129	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. <i>Oncotarget</i> , 2016 , 7, 47565-47575	3.3	31
128	Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016 , 53, 465-71	5.8	114
127	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
126	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015 , 97, 22-34	11	26
125	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
124	Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv077	9.7	69

123	The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. <i>Epigenomics</i> , 2015 , 7, 187-99	4.4	18
122	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 308-16	4	20
121	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16
120	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , 2015 , 10, e0120020	3.7	26
119	Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. <i>International Journal of Cancer</i> , 2014 , 135, 2352-61	7.5	24
118	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
117	Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 447-53	5	3
116	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014 , 16, 3419	8.3	82
115	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
114	Oocyte morphology on day 0 correlates with aneuploidy as detected by polar body biopsy and FISH. <i>Archives of Gynecology and Obstetrics</i> , 2014 , 289, 445-50	2.5	4
113	Sham-controlled implantation after preimplantation genetic screening by polar body biopsy and FISH. <i>Archives of Gynecology and Obstetrics</i> , 2014 , 289, 439-44	2.5	2
112	Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 512-22	5	5
111	Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. <i>Archives of Gynecology and Obstetrics</i> , 2013 , 288, 173-82	2.5	9
110	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
109	High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 150-5	5	19
108	Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. <i>Translational Oncology</i> , 2013 , 6, 305-10	4.9	10
107	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013 , 73, 874-889	2	34
106	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003173	6	90

105	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
104	High expression of crystallin B represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells. <i>International Journal of Cancer</i> , 2013 , 132, 2820-32	7.5	24
103	Genetic characteristics of the human hepatic stellate cell line LX-2. <i>PLoS ONE</i> , 2013 , 8, e75692	3.7	34
102	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012 , 14, R33	8.3	70
101	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012 , 33, 690-702	4.7	31
100	Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers. <i>International Journal of Cancer</i> , 2012 , 130, 1314-8	7.5	9
99	Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1229-39	4.4	32
98	Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals. <i>Cancer Letters</i> , 2012 , 325, 175-88	9.9	20
97	Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. <i>PLoS ONE</i> , 2012 , 7, e50800	3.7	36
96	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. <i>British Journal of Cancer</i> , 2012 , 106, 2016-24	8.7	25
95	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1362-70	4	20
94	Chromosomal mosaicisms in prenatal diagnosis: correlation with first trimester screening and clinical outcome. <i>Journal of Perinatal Medicine</i> , 2012 , 40, 215-23	2.7	6
93	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 645-57	4	44
92	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 134-47	4	411
91	Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. <i>PLoS ONE</i> , 2012 , 7, e45826	3.7	36
90	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
89	A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 769-75	4.4	11
88	Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 549-54	4.4	16

87	Combined treatment with TRAIL and PPAR γ ligands overcomes chemoresistance of ovarian cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 875-86	4.9	19
86	Isolated trisomy 7q21.2-31.31 resulting from a complex familial rearrangement involving chromosomes 7, 9 and 10. <i>Molecular Cytogenetics</i> , 2011 , 4, 28	2	7
85	Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. <i>Human Mutation</i> , 2011 , 32, E2176-88	4.7	45
84	Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. <i>Oncology</i> , 2011 , 80, 12-20	3.6	38
83	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 3304-21	5.6	62
82	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21
81	Is the Ki-67 labelling index ready for clinical use?. <i>Annals of Oncology</i> , 2011 , 22, 500-502	10.3	83
80	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 105-16	9.7	37
79	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. <i>PLoS Biology</i> , 2011 , 9, e1001199	9.7	73
78	Induction of human β -defensins and psoriasin in vulvovaginal human papillomavirus-associated lesions. <i>Journal of Infectious Diseases</i> , 2011 , 204, 391-9	7	30
77	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
76	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <i>Cancer Research</i> , 2010 , 70, 9742-54	10.1	147
75	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2859-68	4	32
74	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. <i>PLoS Genetics</i> , 2010 , 6, e1001183	6	74
73	A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 693-702	4.4	110
72	Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 1046-53	5	16
71	Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity. <i>Human Mutation</i> , 2010 , 31, 60-6	4.7	18
70	Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. <i>Human Mutation</i> , 2010 , 31, E1052-7	4.7	138

69	Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. <i>International Journal of Cancer</i> , 2010 , 126, 2858-62	7.5	22
68	A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. <i>Carcinogenesis</i> , 2009 , 30, 59-64	4.6	78
67	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009 , 18, 4442-56	5.6	91
66	Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. <i>BMC Cancer</i> , 2009 , 9, 438	4.8	9
65	Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition. <i>Cancer Genetics and Cytogenetics</i> , 2009 , 192, 44-7		19
64	Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. <i>International Journal of Cancer</i> , 2009 , 124, 1727-35	7.5	77
63	Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 184-93	5	21
62	Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 407-13	4.4	6
61	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009 , 144, 317-31	4.5	26
60	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2009 , 101, 1456-60	8.7	17
59	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009 , 101, 2048-54	8.7	13
58	Identification of brain- and bone-specific breast cancer metastasis genes. <i>Cancer Letters</i> , 2009 , 276, 212-20	8.9	87
57	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5887-92	2.2	241
56	Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. <i>Translational Oncology</i> , 2009 , 2, 164-73	4.9	12
55	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 109-15	3.5	10
54	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2008 , 99, 974-7	8.7	12
53	Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. <i>British Journal of Haematology</i> , 2008 , 142, 916-24	4.5	30
52	SNPs in ultraconserved elements and familial breast cancer risk. <i>Carcinogenesis</i> , 2008 , 29, 351-5	4.6	47

51	Translationale Forschung in der gynäkologischen Onkologie: Serum-Tumormarker zur Früherkennung des Ovarialkarzinoms. <i>Geburtshilfe Und Frauenheilkunde</i> , 2008 , 68, 830-837	2	2
50	Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. <i>Haematologica</i> , 2008 , 93, 949-50	6.6	13
49	Hereditäres Ovarialkarzinom. <i>Onkologe</i> , 2008 , 14, 1120-1129	0.1	
48	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>American Journal of Human Genetics</i> , 2008 , 82, 937-48	11	218
47	Allelic loss analysis by denaturing high-performance liquid chromatography and electrospray ionization mass spectrometry. <i>Human Mutation</i> , 2007 , 28, 303-11	4.7	3
46	Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. <i>International Journal of Cancer</i> , 2007 , 121, 683-8	7.5	26
45	Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. <i>Oncogene</i> , 2007 , 26, 2685-94	9.2	26
44	The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. <i>Carcinogenesis</i> , 2007 , 28, 423-6	4.6	27
43	An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 458-66	12.9	41
42	Asservierung von Biomaterialien für translationale Fragestellungen im Rahmen aktueller Brustkrebsstudien. Überblick und Empfehlungen. <i>Geburtshilfe Und Frauenheilkunde</i> , 2007 , 67, 451-459	2	0
41	Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. <i>Endocrine-Related Cancer</i> , 2007 , 14, 267-77	5.7	29
40	Premature ovarian failure in a patient with a complex chromosome rearrangement involving the critical region Xq24, characterized by analysis using fluorescence in situ hybridization by chromosome microdissection. <i>Fertility and Sterility</i> , 2007 , 88, 1677.e9-13	4.8	3
39	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. <i>American Journal of Human Genetics</i> , 2007 , 81, 1186-200	11	204
38	Genetic background of different cancer cell lines influences the gene set involved in chromosome 8 mediated breast tumor suppression. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 612-27	5	24
37	Characterization of two supernumerary marker chromosomes in a patient with signs of Klinefelter syndrome, mild facial anomalies, and severe speech delay. <i>American Journal of Medical Genetics, Part A</i> , 2006 , 140, 488-95	2.5	5
36	Gene Expression Profiling of Epithelial Ovarian Cancer. <i>Current Genomics</i> , 2006 , 7, 115-135	2.6	3
35	Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. <i>Carcinogenesis</i> , 2006 , 27, 2201-8	4.6	47
34	Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. <i>Carcinogenesis</i> , 2006 , 27, 1655-60	4.6	40

33	Proof of partial imbalances 6q and 11q due to maternal complex balanced translocation analyzed by microdissection of multicolor labeled chromosomes (FISH-MD) in a patient with Dandy-Walker variant. <i>Cytogenetic and Genome Research</i> , 2006 , 114, 235-9	1.9	9
32	Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer. <i>Breast Cancer Research</i> , 2005 , 7, R775-9	8.3	9
31	The impact of electrical charge on the viability and physiology of dendritic cells. <i>Scandinavian Journal of Immunology</i> , 2005 , 62, 399-406	3.4	19
30	A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. <i>Oncogene</i> , 2005 , 24, 869-79	9.2	7
29	Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. <i>Oncogene</i> , 2005 , 24, 1053-65	9.2	162
28	Simultaneous congener-specific determination of selected organochlorine compounds and nitro musks in human whole blood samples by solid-phase extraction and capillary gas chromatography with electron capture detection. <i>Journal of Analytical Toxicology</i> , 2005 , 29, 110-7	2.9	5
27	An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances REL β In Vitro Transforming Activity.. <i>Blood</i> , 2005 , 106, 2617-2617	2.2	
26	The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. <i>Gynecologic Oncology</i> , 2004 , 95, 89-94	4.9	20
25	Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. <i>Human Mutation</i> , 2004 , 24, 534	4.7	61
24	Limited relevance of the CHEK2 gene in hereditary breast cancer. <i>International Journal of Cancer</i> , 2004 , 110, 320-5	7.5	65
23	A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. <i>Auris Nasus Larynx</i> , 2004 , 31, 149-53	2.2	19
22	Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. <i>Human Mutation</i> , 2003 , 22, 103-4	4.7	26
21	Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. <i>International Journal of Cancer</i> , 2002 , 97, 472-80	7.5	188
20	Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 782, 99-104	3.2	17
19	Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. <i>Journal of Investigative Dermatology</i> , 2001 , 116, 472-4	4.3	11
18	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. <i>Cancer</i> , 2001 , 91, 534-540	6.4	77
17	Highly comprehensive karyotype analysis by a combination of spectral karyotyping (SKY), microdissection, and reverse painting (SKY-MD). <i>Chromosome Research</i> , 2001 , 9, 395-402	4.4	16
16	Mutation analysis of p53 in ovarian tumors by DHPLC. <i>Journal of Proteomics</i> , 2001 , 47, 73-81		49

15	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation 2001 , 91, 534		1
14	Identification of specific BRCA1 and BRCA2 variants by DHPLC. <i>Human Mutation</i> , 2000 , 16, 345-53	4.7	76
13	Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany. <i>Human Mutation</i> , 2000 , 16, 529-30	4.7	11
12	Comparison of comparative genomic hybridization and interphase fluorescence in situ hybridization in ovarian carcinomas: possibilities and limitations of both techniques. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 122, 7-12		12
11	Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization. <i>American Journal of Pathology</i> , 2000 , 156, 1827-33	5.8	31
10	A Fast, Highly Sensitive and Cheap Tool for Mutation Analysis of Complex Genes. <i>Disease Markers</i> , 1999 , 15, 118-118	3.2	78
9	An easy and reliable procedure of microdissection technique for the analysis of chromosomal breakpoints and marker chromosomes. <i>Chromosome Research</i> , 1999 , 7, 355-62	4.4	24
8	A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. <i>Human Mutation</i> , 1999 , 14, 333-9	4.7	90
7	Simian Y chromosomes: species-specific rearrangements of DAZ, RBM, and TSPY versus contiguity of PAR and SRY. <i>Mammalian Genome</i> , 1998 , 9, 226-31	3.2	48
6	Genomic organization and molecular characterization of a gene encoding HsPXF, a human peroxisomal farnesylated protein. <i>Genomics</i> , 1997 , 45, 200-10	4.3	38
5	Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 1996 , 16, 46-54	5	101
4	Comparative mapping of DNA probes derived from the V kappa immunoglobulin gene regions on human and great ape chromosomes by fluorescence in situ hybridization. <i>Genomics</i> , 1995 , 26, 147-50	4.3	34
3	Genomic reorganization and disrupted chromosomal synteny in the siamang (<i>Hylobates syndactylus</i>) revealed by fluorescence in situ hybridization. <i>American Journal of Physical Anthropology</i> , 1995 , 97, 37-47	2.5	72
2	Comparative high-resolution mapping of human and primate chromosomes by fluorescence in situ hybridization. <i>Genomics</i> , 1993 , 18, 381-6	4.3	40
1	Non-radioactive labeling and detection of nucleic acids. III. Applications of the digoxigenin system. <i>Biological Chemistry Hoppe-Seyler</i> , 1990 , 371, 939-51		57